Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination
Trading on The Nasdaq Capital Market under the ticker symbol “PURR”
Hyperliquid Strategies Inc
Hyperliquid Strategies Inc (NASDAQ: PURR) is a digital asset treasury company whose primary focus is to maximize shareholder value through accumulating HYPE, the native token of Hyperliquid, a high-performance blockchain custom-built to house all of finance.
HSI aims to provide capital-efficient and productive access to the HYPE token for U.S. and institutional investors, generating compounding shareholder returns that individual holders may not be able to replicate through staking, yield optimization, and active ecosystem engagement.
HSI is positioned to become the largest HYPE-focused digital asset treasury vehicle capitalizing on Hyperliquid's rapid growth and providing exposure to one of the largest and fastest growing revenue pools in digital assets.
The Sonnet FHAB Mechanism of Action
Our modular FHAB construct utilizes a validated, targeted albumin-binding approach to deliver cytokine payloads with enhanced penetration, retention and local activation directly to the tumor.
Technology Platform
Our FHAB platform utilizes a fully human single-chain antibody fragment (scFv) that binds to and “hitch-hikes” on human serum albumin (HSA) for transport to target tissues.
Technology Platform
Pipeline
Our clinical-stage pipeline comprises five cytokine-derived therapeutic candidates.
Pipeline
Leadership
The Sonnet team combines technical expertise in cytokine biology, as well as extensive experience in drug discovery and development.
TeamEmail Alerts
Stay informed and receive company updates straight to your inbox.